Interventional HIV prevention strategy based on pre-exposure prophylaxis (PrEP) with Truvada® for people in the Île-de-France area (or Paris region) who don't have HIV but who are at high risk of becoming infected with HIV (men who have sex with men (MSM), transgender men and women, heterosexual men and women, sex workers, migrants) in combination with overall prevention services (communautary-based or educational counselling; addiction, social and psychological care; condoms and lubricating gel; clean injection equipment; sexually transmitted diseases (STD) screening and treatment; hepatitis A virus (HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV) vaccinations and post-exposure treatment of HIV infection as soon as possible after diagnosis using an antiretroviral combination recommended by the French Guidelines on HIV treatment). The individual benefit being already demonstrated in clinical trials, the aim is to demonstrate the public health impact of the interventional HIV prevention strategy by reducing the risk of getting HIV-1 infection of at least 15% of new diagnosis of HIV infections among MSM/transgender in the Ile-de-France area after a 3-year period.
Assuming the PrEP efficacy of 80% and that 85% of included participants being MSM - the objective is to evidence a decrease of at least 15% of new diagnosis of HIV infections among MSM in Ile-de-France area. This objective is in the framework of a commitment of large cities against AIDS with the political support of the City of Paris for the "Paris sans SIDA" program and the commitment of the Île-de-France area. Secondary Objectives: * Prevalence of HIV infection at the screening visit (undiagnosed epidemic) * Incidence of HIV infection according to back-calculation approach, and by key subgroups Operational Objectives: * Evaluate the origin of the recruitment according to the risk groups and the outreach actions * Assess linkage to care for PrEP, retention in the study, reasons for consent withdrawal and satisfaction of the participants according to the screening site, the type of PrEP supply, the costs of global care, the key subgroups, the type of counselling, the time from STD testing to initiation of PrEP treatment in study sites * Impact of a less intense counselling than the one provided in the ANRS IPERGAY trial, on adherence and efficacy of PrEP by comparing the incidence observed in MSM enrolled in the current study to that evidenced in the ANRS IPERGAY trial, with a method similar to that used in the Partner demonstration project in Kenya and Uganda. * Impact of the communautary-based and educational counselling Clinical Objectives: * Estimation, in individuals seeking for PrEP and thus getting tested for HIV infection, the prevalence of HIV infection in different key subgroups, which is a surrogate marker of the undiagnosed (or "hidden") epidemic * Evaluate who will become HIV-infected during the course of the study while on PrEP, the proportion of patients on combined antiretroviral treatment and the proposition of patients with a suppressed HIV viral load 12 months after HIV infection * Evaluate the participants' need for post-exposure prophylaxis during the course of the study * Adherence to PrEP (questionnaire and dried blood spots) * Assessment of the PrEP dosing schedule used by MSM participants (daily or intermittent) throughout the course of the study * Assessment of PrEP tolerability and safety * Comprehensive study of incident HIV infections in those on PrEP (incidence, emergence of drug-associated resistance mutations, adherence to PrEP at the closest visit before HIV seroconversion and at previous visits) Participants Behavior: * Acceptability of PrEP (including those who will decline participation in the study) and during the course of the study, and retention in the study. * Impact of PrEP, within a comprehensive prevention offer, on sexual behavior of the participants throughout follow-up * Factors associated with the integration of PrEP in the daily routine of participants: * Qualitative study to explore the motivations, difficulties, behavior and expectations of the participants, their knowledge and communication on their use of PrEP * Reasons related to the choice of the prevention strategy used in terms of dosing schedule (continuous or on demand in MSM) and type of counselling and participation to focus groups. Care Providers Behavior: Evaluation of knowledge, beliefs, perception and practice of the physicians, nurse and peer counselors involved in delivery of PrEP in the study Social epidemiology: Evaluation of social and/or territorial inequalities and disparities Cost-effectiveness of the comprehensive prevention strategy
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
3,257
Associated with: * STD screening/treatment for syphilis, gonorrhoea and chlamydiae * HIV screening/therapy * Questionnaire * Addiction, social or psychological follow-up care if needed * Peer interactive counselling (peer counselors/nurses/physicians experienced with therapeutic education) at the baseline visit and at every follow-up visit up to 6 months. After 6 months, counselling will be provided at the request of participants if they need it. Counselors will remain in contact with the participants between visit to answer any questions relative to PrEP, treatment and prevention, and to facilitate participants interactions with study sites.
Hôpital Avicenne
Bobigny, France
COMPLETEDHôpital Jean Verdier
Bondy, France
COMPLETEDHôpital Ambroise-Paré
Boulogne, France
COMPLETEDHôpital Antoine Béclère
Clamart, France
COMPLETEDHôpital Louis Mourier
Colombes, France
COMPLETEDHôpital Henry Mondor
Créteil, France
COMPLETEDHôpital Raymond Poincaré
Garches, France
COMPLETEDHôpital de Bicêtre
Le Kremlin-Bicêtre, France
COMPLETEDCentre Hospitalier Marc Jacquet
Melun, France
COMPLETEDHôpital Cochin
Paris, France
COMPLETED...and 12 more locations
Reduction of new HIV diagnosis
Number of new HIV infections
Time frame: three years
Number of recent infections
Impact of the study on the total number and on recent HIV infections in Île-de- France, and in each key subgroup
Time frame: three years
Prevalence of HIV-infection at the screening visit (undiagnosed epidemic)
Number of HIV-infected persons at screening visit
Time frame: two years
Incidence of HIV infection
Incidence of HIV infection in Paris and in the Île-de-France area according to back-calculation approach, and by key subgroups (MSM, transgenders, migrants, etc.)
Time frame: three years
Retention in the study
Retention in the study, reasons for consent withdrawal
Time frame: two years
Counselling
Impact of a less intense counselling than the one provided in the ANRS IPERGAY trial, on adherence and efficacy of PrEP
Time frame: three years
Type of counselling
Impact of counselling according to the type of counselling provided: communautary-based or educational
Time frame: three years
Post-exposure prophylaxis
Evaluate the participants' need for post-exposure prophylaxis during the course of the study
Time frame: three years
Adherence to PrEP
Evaluation of adherence by self-administered online questionnaires on last sexual intercourse * Questionnaire on the use of PrEP during the last month prioir to study visit * Dried blood spots to assess TVF-DP and/or FTC-TP in red cells
Time frame: three years
PrEP dosing schedule
Assessment of the PrEP dosing schedule used by MSM participants (daily or intermittent) throughout the course of the study
Time frame: three years
Safety and tolerability
Assessment of PrEP tolerability and safety particularly: incidence of drug-related adverse events, incidence of grade 3-4 adverse events, incidence of adverse events leading to PrEP discontinuation
Time frame: three years
Incident HIV infections
Comprehensive study of incident HIV infections in those on PrEP Incidence of HIV-infection on PrEP * Emergence of drug-associated resistance mutations (in particular FTC and tenofovir- mutations at positions 184, 65, and 70 in reverse transcriptase gene) * Adherence to PrEP at the closest visit before HIV seroconversion and at previous visits
Time frame: three years
Participants Behavior
Acceptability of PrEP (including those who will decline participation in the study) and during the course of the study. Impact of PrEP, within a comprehensive prevention offer, on sexual behavior of the participants throughout follow-up * Number of partners during the previous 2 months * Number of sexual intercourses during the previous 4 weeks * Use of condom at last sexual intercourse * Incidence of STIs
Time frame: three years
Integration of PrEP in the daily routine of participants
* Factors associated with the integration of PrEP in the daily routine of participants \- Qualitative study to explore the motivations, difficulties, behavior and expectations of the participants, their knowledge and communication on their use of PrEP. We will focus on: * Change in the use of sexual networks (internet, sex clubs, backrooms, sauna) * Feeling of sexual well-being during sexual intercourse (less worried about getting HIV infection) * Condom use (withdrawal of condom use)
Time frame: three years
Care Providers Behavior
Evaluation of knowledge, beliefs, perception and practice of the physicians, nurse and peer counselors involved in delivery of PrEP in the study
Time frame: three years
Social epidemiology
* Evaluation of social and/or territorial inequalities and disparities through collection of relevant indicators * Socio-economic status * Social insertion: marital status etc. * Origin (according to Ined definition) : french, french born from immigrant parents, immigrants * Précar score * Socio-economical background (according to IRIS indicator)
Time frame: three years
Cost-effectiveness
Cost-effectiveness of the comprehensive prevention strategy provided in this study
Time frame: three years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.